Since CD33 expression has been described to be much higher on AML cells compared to healthy cells [29], we evaluated the ability of licMABs to preferentially target cells expressing high levels of CD33 in the presence of low CD33-expressing cells. Here, CD33 is linked to acute myeloid leukemia.